--- title: "Pre-market hot trades in US stocks: Insmed pre-market down 10.21%; Fundrise Innovation Fund LLC pre-market up 9.70%" type: "News" locale: "en" url: "https://longbridge.com/en/news/285538493.md" description: "Insmed pre-market down 10.21%; Fundrise Innovation Fund LLC pre-market up 9.70%; Global Engine pre-market up 77.29%; agilon health pre-market up 46.50%; Octave Specialty pre-market up 35.07%" datetime: "2026-05-07T11:17:33.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285538493.md) - [en](https://longbridge.com/en/news/285538493.md) - [zh-HK](https://longbridge.com/zh-HK/news/285538493.md) --- # Pre-market hot trades in US stocks: Insmed pre-market down 10.21%; Fundrise Innovation Fund LLC pre-market up 9.70% **Pre-market Hot Trades in US Stocks** Insmed is down 10.21% in pre-market trading. Based on recent key news: 1. On May 7, Insmed reported a first-quarter earnings per share of -$0.76, below market expectations, leading to a decline in stock price. According to the company's financial report, the net income was -$163.6 million, and analysts' ratings remain "Buy," but the poor performance has raised market concerns. 2. On May 6, Insmed's TPIP and INS1148 drugs are still in the experimental stage and have not received approval in any region. Although these drugs have potential market prospects, the current R&D status has failed to boost investor confidence. 3. On May 4, Insmed's press release via PR Newswire did not provide sufficient positive information to support the stock price, resulting in a lukewarm market response. The biopharmaceutical industry faces R&D risks, and market volatility has intensified. Fundrise Innovation Fund LLC is up 9.70% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Top Gainers in Pre-market US Stocks** Global Engine is up 77.29% in pre-market trading. Based on recent news: 1. On May 6, Global Engine Group Holding Ltd. announced a significant breakthrough in new technology R&D. This news boosted market confidence, leading to a substantial increase in stock price. 2. On May 5, the company released its latest quarterly financial report, showing that its revenue and profit exceeded market expectations. This strong financial performance further propelled the stock price upward. 3. On May 4, analysts generally upgraded their ratings on Global Engine, believing the company has enormous growth potential in the future. This positive analyst rating also supported the stock price. The market reacted positively to the new technology and financial report performance. agilon health is up 46.50% in pre-market trading. Based on recent key news: 1. On May 6, agilon health reported a first-quarter net income of $49 million, far exceeding the market expectation of $11.6 million, driving a significant increase in stock price. Source: Reuters 2. On May 4, JP Morgan downgraded agilon health to "Underweight," with a target price of $21, due to persistently high medical utilization rates and high execution risks, resulting in a 7.5% decline in stock price. Source: Reuters 3. On May 6, agilon health's content released via Business Wire indicated that improvements in its data and forecasting capabilities, as well as operational process enhancements, further strengthened market confidence. Source: Business Wire The overall performance of the healthcare industry is strong, with significant capital inflows Octave Specialty rose 35.07% in pre-market trading. Based on recent news, 4. On May 6, Octave Specialty Group released its Q1 2026 financial report. The report showed that the company's net premiums increased by 80%, but earnings per share were -$0.13, below market expectations. Nevertheless, the market remains optimistic about its future performance, driving the stock price up. 5. On May 6, analysts rated Octave Specialty Group as "Buy," with no "Hold" or "Sell" ratings. Analysts' optimistic expectations further boosted investor confidence, pushing the stock price higher. 6. On May 6, Wall Street set a 12-month target price for Octave Specialty Group at $13.50, approximately 219.9% higher than the closing price of $4.22 on May 6. The release of this target price attracted more investor attention, leading to a significant increase in the stock price. The insurance industry has performed strongly recently, enhancing investor confidence ### Related Stocks - [INSM.US](https://longbridge.com/en/quote/INSM.US.md) - [VCX.US](https://longbridge.com/en/quote/VCX.US.md) - [GLE.US](https://longbridge.com/en/quote/GLE.US.md) - [AGL.US](https://longbridge.com/en/quote/AGL.US.md) - [OSG.US](https://longbridge.com/en/quote/OSG.US.md) ## Related News & Research - [Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus](https://longbridge.com/en/news/286727771.md) - [Insmed Shareholders Approve Directors, Executive Pay and Auditor](https://longbridge.com/en/news/286618392.md) - [TGT Stock Alert: What to Know as Target Taps Former Walmart Exec](https://longbridge.com/en/news/286957668.md) - [Insmed Insiders Sold Shares Worth Over $3.2M](https://longbridge.com/en/news/286609887.md) - [BUZZ-Semiconductor firm Onto Innovation drops on $1.3 bln convertible offering](https://longbridge.com/en/news/286899307.md)